Filtered By:
Source: CardioBrief
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 307 results found since Jan 2013.
Prominent European Cardiologists Decry Curbs On Industry Support For Docs Attending Medical Meetings
Starting in 2018 European device companies will no longer be allowed to directly sponsor physician attendance at medical meetings. In response, three prominent European interventional cardiologists warn that the change could have dire consequences, stifling education and potentially reducing attendance at European medical meetings by 30-50%. In the US physicians can still enjoy free meals. But,...Click here to continue reading...
Source: CardioBrief - December 3, 2015 Category: Cardiology Authors: Larry Husten Tags: Policy & Ethics conflict of interest Europe meetings Source Type: blogs
Encouraging Results Found In Long Term TAVR Registry
Since it’s first FDA approval in late 2011 the use of transcatheter aortic valve replacement therapy (TAVR) has grown dramatically– but not dangerously or explosively– in the US. Now accumulating data from a central national registry provides the best picture yet of the evolution and current status of TAVR. The TVT Registry, which is run by the Society of Thoracic Surgeons (STS)...Click here to continue reading...
Source: CardioBrief - November 30, 2015 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery Policy & Ethics CMS CoreValve Sapien TAVR TVT Registry Source Type: blogs
CMS Proposal Would Plug Up Watchman Reimbursement
Medicare is proposing to put severe constraints on reimbursement for percutaneous left atrial appendage closure using the Boston Scientific Watchman device to prevent stroke in patients with nonvalvular atrial fibrillation. On Tuesday afternoon the Centers for Medicare & Medicaid Services (CMS) issued the draft of a restrictive national coverage determination (NCD) for Watchman that would almost certainly apply the...Click here to continue reading...
Source: CardioBrief - November 11, 2015 Category: Cardiology Authors: Larry Husten Tags: Heart Rhythms Interventional Cardiology & Surgery People, Places & Events Policy & Ethics AF Boston Scientific CMS left atrial appendage closure NCD Watchman Source Type: blogs
Waiting For ISCHEMIA: Why Won’t Cardiologists Enroll Patients?
One of the most important unanswered questions in medicine today– the best treatment for stable ischemic heart disease– may never get a satisfactory answer because cardiologists are unwilling to enter their patients in a clinical trial. One major reason why the question is urgent: about a third of the 1 million PCI procedures performed each year in the...Click here to continue reading...
Source: CardioBrief - November 8, 2015 Category: Cardiology Authors: Larry Husten Tags: Uncategorized catheterization COURAGE ischemia NIH optimal medical therapy PCI Source Type: blogs
Clot Extraction For Stroke: Beware The Hype
Clot extraction (thrombectomy) for stroke has been on a roll lately. After the failure of a series of trials a few years ago investigators and industry went back to the drawing board. The result of their efforts– a new and improved thrombectomy– has brought about a dramatic reversal of fortune for the technology. In the past year five newer trials...Click here to continue reading...
Source: CardioBrief - November 3, 2015 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics stroke thrombectomy Source Type: blogs
Primary PCI Guideline Update: Multivessel Interventions In, Thrombectomy Out
The guidelines for primary PCI for ST-elevation MI (STEMI) have been updated to reflect major findings from recent trials: PCI of a noninfarct artery is now acceptable for some STEMI patients with multivessel disease. In previous guidelines PCI of noninfarct arteries had been considered unsafe. Routine thrombectomy prior to primary PCI for stent implantation is now...Click here to continue reading...
Source: CardioBrief - October 21, 2015 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery MI/ACS guidelines multivessel disease primary PCI thrombectomy Source Type: blogs
New York Times: Indiana Cardiologist Accused Of Performing Unnecessary Procedures
Just when you thought it was safe to read the paper again, along comes a New York Times report suggesting that not all cardiologists have learned the seemingly obvious lessons from the overuse scandals from the past decade. In a front page article in Sunday’s business section, Julie Creswell writes about the ongoing controversy and scandal involving cardiologist Arvind Gandhi,...Click here to continue reading...
Source: CardioBrief - October 18, 2015 Category: Cardiology Authors: Larry Husten Tags: Heart Rhythms People, Places & Events Policy & Ethics Arvind Gandhi ICDs Munster unnecessary procedures Source Type: blogs
The Expanding Universe: JAMA Announces New Cardiology Journal
Warning: snark and cynicism ahead. I’ve said it before and I’ll say it again: what the world needs now is another cardiology journal. And so, as if they were reading my mind and the collective mind of the cardiology community, the AMA announced today the launch of a new journal, JAMA Cardiology. The editor-in-chief will...Click here to continue reading...
Source: CardioBrief - October 12, 2015 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Bonow cardiology journals JAMA JAMA Cardiology JAMA Internal Medicine Rita Redberg Source Type: blogs
‘Cardiology On A Collision Course With Specialty Pharmaceutical Pricing Models’
The recent approval of two new expensive cholesterol drugs “sets the practice of cardiology on a collision course with specialty pharmaceutical pricing models that were previously reserved for drugs that benefited relatively limited patient populations,” according to the authors of a perspective published in the New England Journal of Medicine. Until now cardiologists and other doctors treating the...Click here to continue reading...
Source: CardioBrief - October 7, 2015 Category: Cardiology Authors: Larry Husten Tags: Policy & Ethics Prevention, Epidemiology & Outcomes Amgen cholesterol drug cost insurance PCSK9 Regeneron Sanofi Source Type: blogs
New Concerns Raised About Bioprosthetic Aortic Valves
New, potentially important concerns have been raised about bioprosthetic aortic valves, both those implanted during surgery and those during a catheter-based procedure (TAVR). Investigators from three separate groups reported on their troubling findings in a paper published in the New England Journal of Medicine. The article was accompanied by both an editorial and a perspective from the FDA....Click here to continue reading...
Source: CardioBrief - October 5, 2015 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Aortic valve bioprosthesis TAVR Thrombus Source Type: blogs
A Coke, A Smile, And 120 Million Dollars
As I’ve reported in the past Coca-Cola has a long history of giving money to medical organizations and researchers. Now we know just how much. In response to a New York Times story this summer, Coke has disclosed details of its financial support to a great number and broad variety of health organizations and initiatives. Over the past five years, it...Click here to continue reading...
Source: CardioBrief - September 24, 2015 Category: Cardiology Authors: Larry Husten Tags: Diabetes People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes Uncategorized American College of Cardiology Coca Cola Coke conflict of interest soda sugar Source Type: blogs
Required Reading: Cardiologists Gone Wild
At first glance it might appear that cardiologists are the worst people on earth. In his blog post “Cardiologists and Chinese Robbers“ Scott Alexander lists a long string of horrible misdeeds that might lead you to prefer an encounter in a dark alley with a Mafia henchman instead of a cardiologist: You may have read about one...Click here to continue reading...
Source: CardioBrief - September 21, 2015 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes cardiologists Source Type: blogs
President Obama Nominates Cardiologist Rob Califf To Lead FDA
Before going to the FDA Califf had most recently been the vice chancellor of clinical and translational research at Duke University. As I have previously reported, Califf initially gained national attention in the 1980s as one of the pioneers of clinical trials involving thrombolysis for acute myocardial infarction, which at the time was one of the hottest...Click here to continue reading...
Source: CardioBrief - September 15, 2015 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Califf FDA Source Type: blogs
Survey: Yearly Pay For Cardiologists Hits $542,000
A newly-released survey finds that compensation for cardiologists grew to $542,000 in 2014. This represents a $30,000 increase from 2013 and brings the total close to the previous high of $548,000 in 2012. The increase may reflect an over-representation of private physicians in the survey released by MedAxiom Consulting, which bills itself as the nation’s top cardiovascular service...Click here to continue reading...
Source: CardioBrief - September 15, 2015 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Uncategorized cardiologist pay salary Source Type: blogs
Growing Problem: When Should Drugs Be Discontinued?
There is an entire medical-industrial complex devoted to discovering and testing drugs to treat cardiovascular disease. Unfortunately there is a near complete absence of efforts to figure out if and when these same drugs should be discontinued. Consider Desmond Julian. The very distinguished cardiologist has been nearly killed by his profession on multiple occasions. In a State-of-the-Art...Click here to continue reading...
Source: CardioBrief - September 8, 2015 Category: Cardiology Authors: Larry Husten Tags: Policy & Ethics Prevention, Epidemiology & Outcomes Cardiovascular disease drugs elderly long term use polypharmacy Source Type: blogs
